Get the Stockscreener App
8.49
4.94%
0.40
After Hours:
8.52
0.03
+0.35%
Atara Biotherapeutics Inc stock is traded at $8.49, with a volume of 260.43K.
It is up +4.94% in the last 24 hours and down -36.07% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$8.09
Open:
$8.15
24h Volume:
260.43K
Relative Volume:
1.25
Market Cap:
$48.90M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.3296
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+22.51%
1M Performance:
-36.07%
6M Performance:
-11.84%
1Y Performance:
-45.23%
1-Day Range:
$7.85
$8.64
1-Week Range:
$6.92
$8.64
52-Week Range:
$5.40
$39.50
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4244
Address
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
8.49 | 48.90M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - GlobeNewswire Inc.
(ATRA) Investment Analysis - Stock Traders Daily
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - Markets Insider
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - Markets Insider
Atara stock holds Neutral rating after workforce cut - Investing.com India
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - Markets Insider
Atara reduction in workforce to impact 50% of current employees - MSN
2025-01-27 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics Sees Its Share Price Fall - San Fernando Valley Business Journal
Atara to cut 50% of workforce amid FDA woes - MSN
Atara to cut 50% of workforce amid FDA woes (ATRA:NASDAQ) - Seeking Alpha
Atara Biotherapeutics’ (ATRA) “Neutral” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Forecast for ATRA FY2024 Earnings? - Defense World
Stifel cuts Atara Biotherapeutics target to $5, holds rating - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW - Defense World
Atara extends losses after FDA clinical hold - MSN
Clinical hold follows CRL for Atara - The Pharma Letter
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics stock hits 52-week low at $6.4 amid challenges - Investing.com
Atara, Already Slapped With CRL, Gets A Clinical Hold As Well - News & Insights
Stifel cuts Atara Biotherapeutics target to $5, holds rating By Investing.com - Investing.com UK
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs - AOL
US FDA puts clinical hold on Atara's trials for cancer cell therapies - Reuters
Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha
Atara's New Drug Applications Placed on Hold by FDA - MarketWatch
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 - Business Wire
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate - MSN
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues - Seeking Alpha
Trend Tracker for (ATRA) - Stock Traders Daily
Canaccord Genuity Group Issues Pessimistic Forecast for Atara Biotherapeutics (NASDAQ:ATRA) Stock Price - Defense World
Atara stock plummets on FDA setback for EBV drug - MSN
Atara Bio reiterated at Buy by Canaccord on expected Ebvallo manufacture - Investing.com Canada
Atara In Disarray As Shares Sink On Ebvallo CRL - News & Insights
Atara down 41% on Ebvallo CRL - The Pharma Letter
Atara Biotherapeutics Provides Update on Review of Strategic Alternatives for CAR-T Assets - Marketscreener.com
US FDA declines to approve Atara Biotherapeutics' cancer therapy - MSN
Atara Biotherapeutics Shares Plunge 38% Following FDA Response t - GuruFocus.com
Atara sinks on Ebvallo CRL, seeks strategic alternatives - BioWorld Online
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates - Benzinga
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) - Marketscreener.com
Stock market news: Atara Biotherapeutics -33.28%, Blaize Holdings -26.46% among biggest losers during mid day trading - Business Upturn
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy - BioSpace
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings - Benzinga
Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application - Yahoo Finance
Atara's allogeneic Epstein-Barr treatment hit with CRL - FirstWord Pharma
Atara Shares Sink After FDA Stalls Cancer Treatment - MarketWatch
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):